@article{Jacobs_A-2024_182192,
title = {Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19},
author = {Jacobs, A. and Morley, S. and Samuel, K. and Morgan, K. and Boswell, L. and Kendall, T. and Dorward, D. and Fallowfield, J. and Hayes, P. and Plevris, J.},
month = {aug},
year = {2024},
abstract = {Metabolic dysfunction-associated steatotic liver disease (MASLD), characterised by hepatic lipid accumulation, causes inflammation and oxidative stress accompanied by cell damage and fibrosis. Liver injury (LI) is also frequently reported in patients hospitalised with coronavirus disease 2019 (COVID-19), while pre-existing MASLD increases the risk of LI and the development of COVID-19-associated cholangiopathy. Mechanisms of injury at the cellular level remain unclear, but it may be significant that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19, uses angiotensin-converting expression enzyme 2 (ACE2), a key regulator of the ‘anti-inflammatory’ arm of the renin-angiotensin system, for viral attachment and host cell invasion.},
pages = {3705-3716},
volume = {30},
issue = {31},
journal = {World Journal of Gastroenterology},
publisher = {Baishideng Publishing Group},
url = {http://dx.doi.org/10.3748/wjg.v30.i31.3705},
}
